The SLCO1B1 c.521 T>C variant (rs4149056) is not associated with muscular symptoms or PCSK9-inhibitor prescription in patients with severe hypercholesterolemia and contemporary lipid lowering therapy

In patients with severe hypercholesterolemia on contemporary statin therapy, the SLCO1B1 c.521 T > C variant was not associated with SAMS, reduced statin use, or increased prescription of PCSK9 inhibitors. The SLCO1B1 c.521 T > C variant appears to have no clear clinical relevance, but testing for it may potentially be harmful, as fear of side effects could result in statin undertreatment.